Steady-state pharmacokinetic comparison of a new, once-daily, extended-release morphine formulation (Morphelan™) and OxyContin® twice daily

Journal of Oncology Pharmacy Practice

Volumn 7, Issue 1, 2001, Pages 1-8

  Eliot, Lise ^a   Geiser, Rita ^a   Loewen, Gordon ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Extended release; Morphine; Oxycodone; Pain; Pharmacokinetics; Sustained release

Indexed keywords

MORPHELAN; MORPHINE SULFATE; NALOXONE; OXYCODONE;

ARTICLE; BACKACHE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; HEADACHE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MICTURITION DISORDER; NAUSEA; NORMAL HUMAN; PARANOIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STEADY STATE; VERTIGO; VOLUNTEER;

EID: 0035723876     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155201jp075oa     Document Type: Article

References (13)

1. Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine
2. Long-acting opioids for chronic pain: Pharmacotherapeutic opportunities to enhance compliance, quality of life, and analgesia
3. Steady-state pharmacokinetic comparison of Morphelan ROER (Morphine Sulfate Rapid Onset Extended Release) once-a-day and morphine oral solution administered q4h around-the-clock in healthy volunteers
4. Steady-state pharmacokinetic comparison of a new once-a-day dual-release oral morphine sulfate formulation and a twice-a-day controlled-release oral morphine formulation in patients with moderate-to-severe chronic pain
5. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone
6. Steady-state bioavailability of controlled-release oxycodone in normal subjects
7. Metropolitan Life Insurance Company Height and Weight Table for Men
8. Sprinkle dosing of a new, once-a-day oral extended-release morphine formulation, Morphelan ROER
9. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better
10. The effect of prescribed daily dose frequency on patient medication compliance
11. Long-term patient compliance with prescribed regimens of calcium channel blockers